血清生物标志物特征液体活检用于早期胰腺癌诊断
研究基于斯堪的纳维亚病例对照队列(16例I期、132例II期、65例III期、230例IV期PDAC及888例对照)建立29种血清生物标志物特征,并在美国独立队列(15例I期、75例II期、15例III期、38例IV期及219例对照)中验证。该特征区分I-II期PDAC与对照的ROC曲线下面积均为0.96。
要点
- 29种血清生物标志物特征可区分早期(I-II期)PDAC与对照,AUC为0.96。
- 该特征在斯堪的纳维亚和美国独立队列中均显示AUC 0.96。
- 研究为病例对照设计,尚需前瞻性验证。
核心结论
- 血清生物标志物特征可能成为检测早期局限性PDAC的可行方法,但需前瞻性验证支持。
研究设计与样本
- 病例对照研究,斯堪的纳维亚队列纳入16例I期、132例II期、65例III期、230例IV期PDAC及888例对照。
- 美国独立验证队列纳入15例I期、75例II期、15例III期、38例IV期PDAC及219例对照。
- 采用抗体微阵列平台识别与早期PDAC相关的血清生物标志物特征。
主要发现
- 斯堪的纳维亚队列中,生物标志物特征区分I-II期PDAC与对照的ROC曲线下面积为0.96。
- 该特征由29种生物标志物组成,在美国独立队列中区分I-II期PDAC与对照的ROC曲线下面积亦为0.96。
关键数值与推荐
- 29种血清生物标志物特征区分I-II期PDAC与对照的AUC为0.96(斯堪的纳维亚队列)。
- 同一特征在美国独立队列中区分I-II期PDAC与对照的AUC为0.96。
临床怎么用
- 该血清生物标志物特征有望用于早期PDAC检测,但当前证据来自病例对照研究,需前瞻性验证后方可临床推广。
局限性
- 研究为病例对照设计,结论需前瞻性验证研究支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival of < 10% because of diffuse symptoms leading to late-stage diagnosis. That survival could increase significantly if localized tumors could be detected early. Therefore, we used multiparametric analysis of blood samples to obtain a novel biomarker signature of early-stage PDAC. The signature was derived from a large patient cohort, including patients with well-defined early-stage (I and II) PDAC. This biomarker signature was validated subsequently in an independent patient cohort. PATIENTS AND METHODS: The biomarker signature was derived from a case-control study, using a Scandinavian cohort, consisting of 16 patients with stage I, 132 patients with stage II, 65 patients with stage III, and 230 patients with stage IV PDAC, and 888 controls. This signature was validated subsequently in an independent case-control cohort in the United States with 15 patients with stage I, 75 patients with stage II, 15 patients with stage III, and 38 patients with stage IV PDAC, and 219 controls. An antibody microarray platform was used to identify the serum biomarker signature associated with early-stage PDAC. RESULTS: Using the Scandinavian case-control study, a biomarker signature was created, discriminating samples derived from patients with stage I and II from those from controls with a receiver operating characteristic area under the curve value of 0.96. This signature, consisting of 29 biomarkers, was then validated in an independent case-control study in the United States. The biomarker signature could discriminate patients with stage I and II PDAC from controls in this independent patient cohort with a receiver operating characteristic area under the curve value of 0.96. CONCLUSION: This serum biomarker signature might represent a tenable approach to detecting early-stage, localized PDAC if these findings are supported by a prospective validation study.
引用
- Mellby LD, Nyberg AP, Johansen JS, et al. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. J Clin Oncol. 2018. PMID: 30106639. doi:10.1200/JCO.2017.77.6658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。